




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/46, C07D 451/62 C07D 451/06, 491/20	A1	(11) International Publication Number: WO 90/14088 (43) International Publication Date: 29 November 1990 (29.11.90)
(21) International Application Number: PCT/US90/00292 (22) International Filing Date: 16 January 1990 (16.01.90) (30) Priority data: PCT/US89/02176 17 May 1989 (17.05.89) WO (34) Countries for which the regional or international application was filed: US et al. (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): CHENARD, Bertrand, L. [US/US]; 7 Whaling Drive, New London County, Waterford, CT 06385 (US).		(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US). (81) Designated States: FI, HU, NO, RO, SU, US. Published <i>With international search report.</i>

(54) Title: 2-PIPERIDINO-1-ALKANOL DERIVATIVES AS ANTIISCHEMIC AGENTS



(I)

(57) Abstract

2-(8-Azabicyclo[3.2.1]oct-8-yl)alkanols of formula (I), wherein Q is S or CH=CH; X is H, OH or another aromatic substituent; R is hydrogen, alkyl, alkenyl or alkynyl; Y and Y¹ are taken together and are arylmethylene or aralkylmethylene (or a corresponding epoxy derivative) or Y and Y¹ are taken separately and Y is hydrogen or OH, and Y¹ is aryl, aralkyl, arylthio, or aryloxy; and structurally related 2-(piperidino)alkanols; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America


-1-

2-PIPERIDINO-1-ALKANOL DERIVATIVES
AS ANTIISCHEMIC AGENTS

Background of the Invention

The present invention is directed to neuroprotective (antiischemic and excitory aminoacid receptor blocking) 2-piperidino-1-alkanol derivatives defined by the formulas (I), (II) and (III) below; pharmaceutically acceptable salts thereof; a method of using these compounds in the treatment of stroke or CNS degenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease; and to certain intermediates therefor.

Ifenprodil is a racemic, so-called dl-erythro compound having the relative stereochemical formula



which is marketed as a hypotensive agent, a utility shared by a number of close analogs; Carron et al., U.S. Patent 3,509,164; Carron et al., Drug Res., v. 21, pp. 1992-1999 (1971). More recently, ifenprodil has been shown to possess antiischemic and excitory aminoacid receptor blocking activity; Gotti et al., J.


-2-

Pharm. Exp. Therap., v. 247, pp. 1211-21 (1988); Carter
et al., loc. cit., pp. 1222-32 (1988). See also French
Patent 2546166. A goal, substantially met by the
present invention, has been to find compounds
possessing such neuroprotective effect in good measure,
while at the same time having lowered or no significant
hypotensive effect.

Certain structurally related 1-phenyl-3-(4-aryl-4-
acyloxypiperidino)-1-propanols have also been reported
to be useful as analgesics, U.S. Patent 3,294,804; and
1-[4-(amino- and hydroxy-alkyl)phenyl]-2-(4-hydroxy-4-
tolylpiperazino)-1-alkanols and alkanones have been
reported to possess analgesic, antihypertensive,
psychotropic or antiinflammatory activity, Japanese
Kokai 53-02,474 (CA 89:43498y; Derwent Abs. 14858A) and
53-59,675 (CA 89:146938w; Derwent Abs. 48671A).

Summary of the Invention

The present invention is directed to compounds of
the formula



wherein

-3-



R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

X is hydrogen, (C₁-C₃)alkyl, halo, OR¹, OCOR¹, CO₂R¹, SR¹, NHR¹, NHCOR¹, CONH₂ or CN;

R¹ is hydrogen or (C₁-C₃)alkyl;


Q is S or CH=CH;

Y and Y¹ are taken together and are



Y and Y¹ are taken separately, and

20 Y is hydrogen or OH, and Y¹ is




25

Y is hydrogen and Y¹ is

30

-4-



;

5

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;


 Q^1 is independently a value of Q as defined above;10 X^1 is independently a value of X as defined above;

and

Z is O, S, SO or SO₂;

compounds of the formula

15




--- (II)

20


wherein

D is


25



,



or




;

30


 Y^2 and Y^3 are taken together and are

-5-



or

5




; or

10

Y^2 and Y^3 are taken separately, and Y^2 is OH and Y^3 is


15



;

Y^9 is

20



;


25

and R , R^1 , X , X^1 , Q , Q^1 , n and m are as defined above;

and compounds of the formula

30

-6-



10 wherein

Y^4 is H; and

R , R^1 , Q , Q^1 , X , X^1 and Z are as defined above;

and the pharmaceutically acceptable acid addition salts of these compounds.

15 The expression "pharmaceutically acceptable acid addition salts" is intended to include but is not limited to such salts as the hydrochloride, hydrobromide, hydroiodide, nitrate, hydrogen sulfate, dihydrogen phosphate, mesylate, maleate, and succinate.


20 Such salts are conventionally prepared by reacting the free base form of the compound (I), (II) or (III) with an appropriate acid, usually one molar equivalent, and in a solvent. Those salts which do not precipitate directly are generally isolated by concentration of the solvent and/or addition of a non-solvent.

25

The preferred compounds of the present invention generally have R as methyl and possess 1S*, 2S* or threo relative stereochemistry at the 1- and 2-positions of the propanol chain, i.e.,

30

-7-



5

Furthermore, regardless of the value of R, preferred compounds of the present invention are of the formula (I) or (II) having Y and Y¹ or Y² and Y³ taken separately, further having Y or Y² as OH, or Y¹ as
10 -Z(C₄H₃O¹)X¹; or are of the formula (III). The preferred value of Z in all cases is S.


The present invention is also directed to pharmaceutical compositions and to methods of treating a
15 mammal, particularly man, suffering a central nervous disorder, which comprises administering to said mammal a neuroprotective effective amount of a compound of the formula (I), (II) or (III). Said compositions and
20 methods are particularly valuable in the treatment of stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease and related disorders of the central nervous system.

The present invention is further directed to
25 intermediate compounds of the formula

25

30

-8-



10 wherein

A and B are taken together and are oxygen, forming, together with the carbon to which they are attached a carbonyl group, or A and B are taken separately and A is hydrogen and B is hydroxy;

15 X^2 is hydrogen, (C_1-C_3) alkyl, halo, OR^1 , OR^2 , $COOR^1$, $OCOR^1$, SR^1 , SR^2 , NHR^1 , NR^1R^3 , $NHCOR^1$, $CONH_2$ or CN;


R^1 is hydrogen or (C_1-C_3) alkyl;

R^2 is a conventional hydroxy or mercaptan

20 protecting group;


R^3 is a conventional amino protecting group;

Y^5 and Y^6 are taken together and are



30

-9-




; or

5

Y^5 and Y^6 are taken separately and
 Y^5 is hydrogen or OH, and Y^6 is


10



; or

15

Y^5 is hydrogen and Y^6 is



;

20

X^3 is independently a value of X^2 as defined
 above; with the proviso that when A and B are taken
 separately, at least one of X^2 and X^3 is OR^2 , SR^2 or
 NR^1R^3 ;

25


Z is O, S, SO or SO_2 ; and

R, Q, Q^1 , n and m are as defined above;




intermediate compounds of the formula

30

-10-




10 wherein
E is




30 Y^7 and Y^8 are taken separately, and Y^7 is OH and
 Y^8 is

-11-




5 Y^{10} is



10

and A, B, R, R^1 , R^2 , R^3 , Q, Q^1 , X^2 , X^3 , n and m
 are as defined above, with the same proviso concerning
 15 A and B;
 and intermediate compounds of the formula



25 wherein all groups are defined as above, with the same
 proviso concerning A and B.

Those compounds of the formula (I) or (IV)
 specified as endo have the hydroxy group or oxirane
 oxygen on the same side of the piperidine ring as the
 30 ethylene bridge.

-12-

It will be noted that those compounds of the formula (I) to (VI) which are 1-alkanols possess an asymmetric C-1 carbon, while those wherein R is other than hydrogen possess a second asymmetric center at the C-2 carbon of the alcohol. Similarly, in those compounds of the formulas (IV) to (VI) which are 1-alkanones wherein R is other than hydrogen possess a C-2 asymmetric carbon. It will be evident to those skilled in the art of organic chemistry, therefore, that such compounds can be resolved into optical isomers showing equal but opposite rotation of plane polarized light. For example, all of these compounds are potentially resolved by fractional crystallization of their diastereomeric addition salts with an optically active acid, as exemplified below; while the alcohols are also potentially resolved by chromatography or fractional crystallization of esters derived by reaction with activated forms of optically active acids or with optically active isocyanates. Alternatively, optically active forms of certain of the present compounds are obtained by reaction of an appropriate amine with an optically active epoxide, as also exemplified below. Thus, the present invention should not be construed as limited to the racemic forms of the present compounds.


30

-13-

Detailed Description of the Invention

The compounds of the present invention, having the formula (I), (II) and (III) defined above, are readily and generally prepared by nucleophilic displacement followed by reduction of the resulting ketone to alcohol as detailed below.

The precursor ketones are generally initially prepared with -OH, -SH and -NHR¹ groups in protected form, i.e., as -OR², -SR² or -NR¹R³ groups in the compounds of the formulas (IV), (V) and (VI) where A and B are taken together as oxygen to form a carbonyl group. Such protected ketones are generally formed by nucleophilic displacement of an appropriately substituted 2-halo, 2-alkanesulfonyloxy- or 2-arylsulfonyloxy-1-alkanone with an appropriately substituted piperidine derivative, e.g.,



25 wherein X⁴ is typically chloro, bromo, mesyloxy or tosyloxy. This reaction is carried out under conditions typical of nucleophilic displacements in general. Where the two reactants are about equivalent in availability, close to substantially molar

30

-14-

equivalents may be used; although when one is more readily available, it is usually preferred to use that one in excess, in order to force this bimolecular reaction to completion in a shorter period of time.

5 The reaction is generally carried out in the presence of at least 1 molar equivalent of a base, the piperidine derivative itself, if it is readily available, but more usually a tertiary amine which is at least comparable in base strength to the
10 nucleophilic piperidine; and in a reaction inert solvent such as ethanol. If desired, the reaction is catalyzed by the addition of up to one molar equivalent or more of an iodide salt (e.g., NaI, KI). Temperature
15 is not critical, but will generally be somewhat elevated in order to force the reaction to completion within a shorter time period, but not so high as to lead to undue decomposition. A temperature in the range of 50-120°C is generally satisfactory.
20 Conveniently, the temperature is the reflux temperature of the reaction mixture.

As used in the preceding paragraph, and elsewhere herein, the expression "reaction inert solvent" refers to any solvent which does not interact with starting
25 materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

If desired, those ketone intermediates having OH, SH or NHR^1 groups in protected form (OR^2 , SR^2 or NR^1R^3)
30 can be deprotected at this stage by conventional methods. For example, when R^2 is triisopropylsilyl or tert-butyldimethylsilyl, the protecting group is

-15-


conveniently removed by reaction with tetrabutyl-
ammonium fluoride (generally, substantially 2 molar
equivalents) in a reaction inert solvent such as
tetrahydrofuran. When R^2 is benzyl or R^3 is benzyloxy-
carbonyl, the protecting group will generally be
removed by conventional hydrogenolysis over a noble
metal catalyst in a reaction inert solvent, e.g., using
10% Pd/C as catalyst, preferably at low pressures
(e.g., 1-10 atmospheres) and temperatures (e.g.,
20-75°C) and generally in a reaction inert solvent such
as methanol.

Generally excluding ketone intermediates
containing ester groups or protecting groups such as
benzyloxycarbonyl (which will generally be removed
prior to ketone reduction), but otherwise with or
without prior removal of protecting groups, the ketone
intermediates are conveniently converted to
corresponding alcohols by conventional reduction with a
 $LiAlH_4$, usually in excess (e.g., mol for mol), in a
reaction inert solvent such as tetrahydrofuran at
reduced temperature (e.g., -15°C to 15°C).
Alternatively, ketone intermediates, particularly those
containing ester groups, are reduced with a milder
hydride reducing agent such as $NaBH_4$, again usually in
excess, now in a protic solvent such as methanol or
ethanol, generally at somewhat higher temperature,
e.g., 15-45°C.

30

-16-

Any protecting groups which are still in place after ketone reduction are then removed according to the methods described above. Certain other transformations, such as olefin hydrogenation, epoxidation and sodium/liquid NH_3 reduction of epoxides, e.g.,



are also optionally carried out late in the synthetic sequence, e.g., after coupling to form ketone, after removal of protecting groups (so long as the unprotected groups do not interfere with the transformations) and/or after reduction of ketone to alcohol.

Said epoxidations are readily accomplished, for example, by reacting a methylene compound with substantially one molar equivalent of m-chloro-perbenzoic acid in a reaction inert solvent such as CH_2Cl_2 . The reduction of epoxide to alcohol is readily accomplished by conventional sodium/liquid ammonia, generally carried out at temperatures below the boiling point of liquid NH_3 (e.g., at -78°C , the temperature of an acetone-dry ice bath) in the presence of a reaction inert solvent such as tetrahydrofuran.

The starting materials and reagents required for the synthesis of the compounds of the present invention are readily available, either commercially, according to literature methods, or by methods exemplified in Preparations below.

-17-

The present compounds of the formula (I), (II) and (III) possess selective neuroprotective activity, based upon their antiischemic activity and ability to block excitatory amino acid receptors, while at the same time generally having lowered or no significant hypotensive activity. The antiischemic activity of the present compounds is determined according to one or more of the methods which have been detailed previously by Gotti et al. and Carter et al. cited above, or by similar methods. The ability of the compounds of the present invention to block excitatory amino acid receptors is demonstrated by their ability to block N-methyl-D-aspartic acid-induced (NMDA) elevations of cGMP in neonatal rat cerebellums according to the following procedure. Cerebellums from ten 8-14 day old Wistar rats are quickly excised and placed in 4° C. Krebs/bicarbonate buffer, pH 7.4 and then chopped in 0.5 mm x 0.5 mm sections using a McIlvain tissue chopper (The Nickle Laboratory Engineering Co., Gomshall, Surrey, England). The resulting pieces of cerebellum are transferred to 100 ml of Krebs/bicarbonate buffer at 37° C. which is continuously equilibrated with 95:5 O₂/CO₂. The pieces of cerebellum are incubated in such a manner for ninety minutes with three changes of the buffer. The buffer then is decanted, the tissue centrifuged (1 min., 3200 r.p.m.) and the tissue resuspended in 20 ml of the Krebs/bicarbonate buffer. Then, 250 µl aliquots (approximately 2 mg) are removed and placed in 1.5 ml microfuge tubes. To those tubes are added 10 µl of the compound under study from a stock solution followed, after a 10 minute

-18-

incubation period, by 10 μ l of a 2.5 mM solution of NMDA to start the reaction. The final NMDA concentration is 100 μ M. Controls do not have NMDA added. The tubes are incubated for one minute at 37° C. in a shaking water bath and then 750 μ l of a 50 mM Tris-Cl, 5mM EDTA solution is added to stop the reaction. The tubes are placed immediately in a boiling water bath for five minutes. The contents of each tube then are sonicated for 15 seconds using a probe sonicator set at power level three. Ten microliters are removed and the protein determined by the method of Lowry, Anal. Biochem. 100:201-220 (1979). The tubes are then centrifuged (5 min., 10,000 xg), 100 μ l of the supernatant is removed and the level of cyclic GMP (cGMP) is assayed using a New England Nuclear (Boston, Massachusetts) cGMP RIA assay according to the method of the supplier. The data is reported as pmole cGMP generated per mg. protein. Undesired hypotensive activity is also determined by known methods, for example, according to the methods of Carron et al., also cited above.

Such selective neuroprotective antiischemic and excitatory amino acid blocking activities reflect the valuable utility of the present compounds in the treatment of degenerative CNS (central nervous system) disorders such as stroke; and Alzheimer's disease, Parkinson's disease and Huntington's disease; without significant potential for concurrent undue drop in blood pressure. In the systemic treatment of such diseases with a neuroprotective amount of compounds of the formula (I), (II) or (III), the dosage is typically from about 0.02 to 10 mg/kg/day (1-500 mg/day in a

-19-

typical human weighing 50 kg) in single or divided doses, regardless of the route of administration. Of course, depending upon the exact compound and the exact nature of the individual illness, doses outside this
5 range may be prescribed by the attending physician. The oral route of administration is generally preferred. However, if the patient is unable to swallow, or oral absorption is otherwise impaired, the preferred route of administration will be parenteral
10 (i.m., i.v.) or topical.

The compounds of the present invention are generally administered in the form of pharmaceutical compositions comprising at least one of the compounds
15 of the formula (I), (II) or (III), together with a pharmaceutically acceptable vehicle or diluent. Such compositions are generally formulated in a conventional manner utilizing solid or liquid vehicles or diluents as appropriate to the mode of desired administration:
20 for oral administration, in the form of tablets, hard or soft gelatin capsules, suspensions, granules, powders and the like; for parenteral administration, in the form of injectable solutions or suspensions, and the like; and for topical administration, in the form
25 of solutions, lotions, ointments, salves and the like.

The present invention is illustrated by the following examples, but is not limited to the details thereof.

All non-aqueous reactions were run under nitrogen
30 for convenience and generally to maximize yields. All solvents/diluents were dried according to standard

-20-

published procedures or purchased in a predried form.
All reactions were stirred either magnetically or
mechanically. NMR spectra are recorded at 300 MHz and
are reported in ppm. The NMR solvent was CDCl_3 unless
otherwise specified. IR spectra are reported in cm^{-1} ,
generally specifying only strong signals.

5

10

15

20

25

30

-21-

EXAMPLE 1

2-(3-Phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-
(4-(triisopropylsilyloxy)phenyl)-1-propanone

5 A mixture of 3-phenylmethylene-8-azabicyclo-
[3.2.1]octane (1.09 g, 4.87 mmol), 4-(triisopropyl-
siloxy)-alpha-bromopropiophenone (1.88 g, 4.88 mmol)
and triethylamine (1.5 ml, 10.76 mmol) in ethanol (75
ml) was refluxed 22 hours. After cooling, ether (50
10 ml) was added and the mixture was filtered through
diatomaceous earth. The filtrate was concentrated and
chromatographed on silica gel (2 x 6 inches, hexane
then ethyl acetate/hexane gradient) to give 0.56 g
(23%) of an orange oil product; NMR 8.18 (d, 2H), 7.25
15 (t, 2H), 7.12 (d, 3H), 6.86 (d, 2H), 6.29 (s, 1H), 4.08
(m, 1H), 3.47-3.26 (m, 2H), 2.75 (m, 1H), 2.57-2.37 (m,
2H), 2.03-1.72 (m, 4H), 1.6 (m, 1H; partially under
water peak from NMR solvent), 1.40 (d, 3H), 1.25 (m,
3H), 1.09 (d, 18H).

EXAMPLE 2

20 Mixture of (1R*,2S*)- and (1S*,2S*)-2-(3-
phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-
1-(4-(triisopropylsilyloxy)phenyl)-1-propanol

To a slurry of LiAlH₄ (0.61 g, 16.07 mmol) in
25 tetrahydrofuran (50 ml) at 0°C was added title product
of the preceding Example (8.04 g, 15.96 mmol) in
tetrahydrofuran (150 ml) over 15 minutes. The mixture
was stirred 15.5 hours at room temperature, then
carefully quenched with water (1.2 ml), filtered over
30 diatomaceous earth and concentrated to give a yellow

-22-

oil (7.15 g, 89%). This mixture of racemic title products was used directly in the next reaction without purification.

EXAMPLE 3

5 (1S*,2S*)- and (1R*,2S*)-1-(4-hydroxyphenyl)-2-(3-phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol

Title product of the preceding Example (7.15 g, 14.14 mmol) was dissolved in tetrahydrofuran (250 ml) and tetrabutylammonium fluoride (28.5 ml, 28.5 mmol, 1M
10 in tetrahydrofuran) was added all at once. The solution was stirred at room temperature 18 hours, then concentrated and chromatographed on silica gel (4 x 6 inches, ethyl acetate/hexane gradient followed by
15 methanol/ethyl acetate gradient) to give first the racemic (1S*,2S*)-title product (1.58 g) followed by the more polar racemic (1R*,2S*)-title product (2.88 g). (Note that because of the asymmetry in the
20 3-phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl side chain, each of these products is actually a mixture of two racemates).

The (1S*,2S*)-product was recrystallized from ethyl acetate/hexane to give 0.923 g of white solid; mp 175-177°C; NMR includes 4.10 (t, J=7.7Hz, 1H); Anal. C
25 78.77, H 7.90, N 3.92, calcd. C 79.05, H 7.90, N 3.92.

The (1R*,2S*)-product was further purified by radial chromatography with 60% ethyl acetate/hexane elution to give 0.24 g of colorless oil. This oil was
30 crystallized from ether/hexane to give 0.17 g of fluffy solid, mp 78.5-85°C. The latter was converted to its HCl salt by bubbling HCl gas into an ether solution of the compound for 3 minutes. The white precipitate was

-23-

collected and recrystallized from ethanol to yield the
(1R*,2S*)-hydrochloride salt as its half hydrate; mp
215-218°C; NMR (DMSO-d₆) includes 5.17 (s, 1H) and
4.60-3.93 (m, 2H); Anal. C 70.00, H 7.45, N 3.35,
5 calcd. for $\frac{1}{2}$ H₂O C 69.95, H 7.40, N 3.54.

EXAMPLE 4

2-(4-(Phenylthio)piperidino)-1-(4-(tert-butyldimethyl-
silyloxy)phenyl)-1-propanone

10 This product was prepared according to the
procedure of Example 1 using 4-phenylthiopiperidine
(1.13 g, 5.85 mmol), triethylamine (0.82 ml, 5.88
mmol), and 4-(tert-butyldimethylsilyloxy)-alpha-bromo-
15 propiophenone (2.0 g, 5.83 mmol) and a reflux time of
21.5 hours. The product was isolated by silica gel
flash chromatography with an ethyl acetate/hexane
gradient elution. The yield was 1.29 g of title
product as a yellow oil: NMR 8.00 (d, J = 9Hz, 2H),
7.35 (d, J = 7.8Hz, 2H), 7.25 (m, 3H), 6.81 (d, J =
20 8.4Hz, 2H), 4.00 (q, J = 6.8Hz, 1H), 3.03 (m, 1H),
2.91-2.87 (m, 1H), 2.80-2.76 (m, 1H), 2.44 (dt, J =
9.5, 2.6Hz, 1H), 2.29-2.19 (m, 1H), 1.93-1.85 (m, 2H),
1.66-1.52 (m, 2H--partially under water peak from
solvent), 1.22 (d, J = 7.1Hz, 3H), 0.97 (s, 9H), 0.22
25 (s, 6H). Later fractions from the chromatography
yielded an additional 0.51 g of product which had
desilylated during the reaction. This material could
also be converted to the final targeted compounds by
procedures below.

30

-24-

By the same methods 4-(triisopropylsilyloxy)-
alpha-bromopropiophenone (9.97 g, 25.9 mmol) was
converted to chromatographed 2-(4-(phenylthio)piperi-
dino)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanone as
5 a light orange oil: 8.32 g; NMR 8.00 (d, J = 8.8Hz,
2H), 7.37 (dd, J = 1.5, 8.4Hz, 2H), 7.29-7.18 (m, 3H),
6.86 (d, J = 8.8Hz, 2H), 4.02 (q, J = 6.8Hz, 1H),
3.08-3.00 (m, 1H), 2.85 (d, J = 26.2Hz, 1H), 2.75 (d, J
= 16.6Hz, 1H), 2.45 (dt, J = 11, 2.6Hz, 1H), 2.23 (dt,
10 J = 9.8, 2.5Hz, 1H), 1.96-1.88 (m, 2H), 1.71-1.50 (m,
5H), 1.09 (d, J = 7Hz, 18H).

EXAMPLE 5

(1S*,2S*)- and (1R*,2S*)-2-(4-Phenylthio)piperdino)-
15 1(4-(triisopropylsilyloxy)phenyl)-1-propanol

By the method of Example 2, the triisopropyl-
silyloxy product of the preceding Example (8.32 g, 16.7
mmol), using chromatography on silica gel with ethyl
acetate/hexane gradient elution to separate the
20 isomers, was converted to 6.06 g of less polar (1S*,
2S*)-title product as an oil; NMR 7.41 (d, J = 6.7Hz,
2H), 7.32-7.24 (m, 3H), 7.15 (d, J = 8.5Hz, 2H), 6.82
(d, J = 8.4Hz, 2H), 4.14 (d, J = 9.7Hz, 1H), 3.11 (m,
1H), 2.88 (m, 1H), 2.69 (m, 1H), 2.69-2.55 (m, 2H),
2.21 (t, 1H), 2.03 (m, 2H), 1.85-1.58 (m, 3H),
25 1.35-1.20 (m, 2H), 1.23 (d, J = 15Hz, 18H), 1.07 (d, J
= 7Hz, 3H); and to 0.2 g of more polar (1R*,2S*)-title
product; NMR 7.35 (d, J = 7Hz, 2H), 7.28-7.16 (m, 3H),
7.08 (d, J = 9Hz, 2H), 6.78 (d, J = 9Hz, 2H), 4.68 (d,
30 J = 5Hz, 1H), 3.10-2.98 (m, 1H), 2.98-2.87 (m, 1H),

-25-

2.75-2.60 (m, m, 2H), 2.33 (t, J = 9Hz, 1H), 2.16 (t, J = 11Hz, 1H), 1.91 (t, J = 15Hz, 2H), 1.70-1.48 (m, 2H), 1.32-1.12 (m, 4H), 1.06 (d, J = 9Hz, 18H), 0.88-0.78 (m, 3H).

5

EXAMPLE 6

(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylthio)-piperidino)-1-propanol

Method A

10 To a slurry of LiAlH_4 (0.11 g, 2.9 mmol) in tetrahydrofuran (25 ml) chilled to 0°C was added title product of Example 4 (1.29 g, 2.83 mmol) in tetrahydrofuran (50 ml). The reaction was warmed to ambient temperature for 2 hours, refluxed for 3 hours, and left
15 to stir for 72 hours. The mixture was carefully quenched with water and filtered through diatomaceous earth. The filtrate was concentrated to a wet solid, which was taken up in ethyl acetate and washed with brine, dried (CaSO_4), concentrated to afford 0.41 g of
20 white solid, and recrystallized from ether/hexane to give 0.16 g of title product; mp 155-157°C; NMR includes 4.12 (d, 1H); Anal. C 69.57, H 7.28, N 3.95, calcd. C 69.94, H 7.34, N 4.08. The alumina salts from the reaction were Soxhlet extracted with ethyl acetate
25 for 24 hours. Concentration gave an additional 0.3 g of product.

Method B

30 The same product is obtained from the (1S*, 2S*)-title product of the preceding Example by the method of Example 3.

-26-

EXAMPLE 7

(1R*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylthio)-
piperidino)-1-propanol

5 Following the procedure of Example 3, present
title product was obtained from the (1R*,2S*)-title of
Example 5 (0.2 g, 0.4 mmol) and tetrabutylammonium
fluoride (0.8 ml, 0.8 mmol: 1M in tetrahydrofuran) in
tetrahydrofuran (5 ml) at ambient temperature for 72
10 hours. The product was obtained by silica gel flash
chromatography (6 x 1 inches, ethyl acetate/hexane
gradient elution) to give 0.14 g of semi-solid.
Recrystallization from methylene chloride/hexane gave
0.056 g of white solid; mp 124.5-126°C; NMR includes
15 4.72 (d, J = 4.1Hz, 1H); Anal. C 69.68, H 7.24, N 4.14,
calcd. C 69.94, H 7.34, N 4.08.

EXAMPLE 8

(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylsulfonyl)-
piperidino)-1-propanol

20 Title product of Example 6 (0.13 g, 0.378 mmol)
was dissolved in CH₂Cl₂ (20 ml) and m-chloroperoxy-
benzoic acid (0.23 g, 1.133 mmol) was added all at
once. The solution was stirred 23 hours, then the
precipitated material was filtered to give 0.154 g of
25 white solid which was the crude intermediate N-oxide.
The latter was hydrogenated in a Parr apparatus in
methanol (20 ml) with 10% palladium on carbon catalyst
(0.03 g) at 50 psig hydrogen. The reaction was
complete in 6 hours and was filtered through
30 diatomaceous and concentrated to leave 0.166 g of
yellow oil. This oil was taken up in CH₂Cl₂ and washed
with saturated sodium bicarbonate. The organic phase

-27-

was dried (MgSO_4) and concentrated to give 0.106 g of yellow oil, which was crystallized from ethyl acetate/hexane to yield 0.076 g of white solid; mp 169-175°C. A portion of the product (0.045-0.050 g) was further purified by mixing vigorously with saturated sodium bicarbonate and ethyl acetate for 15 minutes. The phases were separated and the aqueous was further extracted with ethyl acetate (2x). The combined organic phase was dried (CaSO_4), concentrated to give a colorless oil, and crystallized from ethyl acetate to give 0.02 g of white powder; mp 195-196°C; NMR 7.88 includes 4.15 (d, $J = 9.7\text{Hz}$, 1H); Anal. C 63.77, H 6.61, N 3.61, calcd. C 63.98, H 6.71, N 3.73:

EXAMPLE 9

(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylsulfinyl)-piperidino)-1-propanol

Title product of Example 6 (0.5 g, 1.46 mmol) was dissolved in CH_2Cl_2 (40 ml) and m-chloroperoxybenzoic acid (0.3 g, 1.48 mmol) was added all at once. After stirring overnight at ambient temperature, the mixture was concentrated directly onto silica gel and flash chromatographed (6 x 1 inches, ethyl acetate/hexane gradient) to give 0.34 g of crude product as a white solid which was further purified by partitioning between saturated NaHCO_3 and ethyl acetate with vigorous stirring for 20 minutes. The phases were separated and the organic layer was concentrated to leave a greasy solid which was crystallized from ethyl acetate/hexane to give 0.122 g of white solid; mp 110°C; NMR includes 4.16 (long range coupled d, $J = 9.7\text{Hz}$, 1H); HRMS 360.1635, calcd. 360.1626.

-28-

EXAMPLE 101-(4-(Benzyloxy)phenyl)-2-(4-benzyl-4-hydroxypiperidino)-1-propanone

5 This product was prepared following the procedure of Example 1 from 4-hydroxy-4-benzylpiperidine (2.0 g, 10.46 mmol), triethylamine (1.46 ml, 10.47 mmol), and 4-benzyloxy-alpha-bromopropiophenone (3.33 g, 10.43 mmol) in ethanol (50 ml) with a reflux period of 24 hours. The present racemic product was obtained after
10 silica gel flash chromatography with ethyl acetate/hexane gradient elution. The yield was 2.88 g (64%) of a yellow solid; NMR 8.06 (d, 2H), 7.52-7.08 (m, 10H), 6.97 (d, 2H), 5.11 (s, 2H), 4.00 (q, 1H),
15 2.72 (s, 2H), 2.72-2.53 (m, 2H), 2.43 (t, 1H), 1.85-1.39 (m, 6H), 1.23 (d, 3H). HRMS 412.2348, calcd. (-OH) 412.2273.

EXAMPLE 11(1S*,2S*)-1-(4-(Benzyloxy)phenyl)-2-(4-benzyl-4-hydroxypiperidino)-1-propanol

20 NaBH₄ (0.25 g, 6.61 mmol) was added all at once to a solution of title product of the preceding Example (2.88 g, 6.70 mmol) in ethanol (50 ml). The mixture was stirred 20 hours at ambient temperature as a
25 precipitate formed. The solid was filtered and dried to yield 0.60 g of present title product; mp 147-148°C; NMR includes 4.17 (d, J = 10Hz, 1H); IR (KBr) 3387, 3024, 2936, 2909, 1611, 1513, 1453, 1239, 1026, 1011, 695. The filtrate from the above reaction was
30 concentrated, the residue partitioned between ethyl acetate and water and the phases separated. The

-29-

aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with water, dried (CaSO_4) and concentrated to give 2.82 g of additional title product.

5

EXAMPLE 12

(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-benzyl-4-hydroxy-piperidino)-1-propanol

10

15

20

25

30

Title product of the preceding Example (0.49 g, 1.14 mmol) and tetrahydrofuran (30 ml) was chilled to -78°C and ammonia gas (30 ml) was condensed into the mixture. Sodium (0.082 g, 3.57 mmol) was added in four pieces. The reaction, which gradually turned blue, was stirred 15 minutes and then quenched with ammonium chloride (0.29 g). The reaction was allowed to warm to ambient temperature, with the ammonia boiling off. The reaction was concentrated and the residue was taken up in ethyl acetate and washed with water and brine. The organic phase was dried (CaSO_4) and concentrated to give 0.39 g of white solid. Recrystallization from hexane gave 0.19 g of present title product; NMR ($\text{DMSO}-d_6$) 7.25-7.11 (m, 5H), 7.08 (d, $J = 8.2\text{Hz}$, 2H), 6.68 (d, $J = 8.6\text{Hz}$, 2H), 4.14 (s, 1H), 4.09 (d, $J = 9.2\text{Hz}$, 1H), 3.33 (s, 2H), 3.30 (s, 1H), 2.74 (m, 1H--partially under water peak from the NMR solvent), 2.60-2.35 (m, 4H--partially under NMR solvent peak), 1.70-1.44 (m, 4H), 0.63 (d, $J = 6.7\text{Hz}$, 3H). Deuterium oxide washed out the singlets at 4.14 and 3.30 ppm.

-30-

This product was recrystallized from ethyl acetate to give purified title product; mp 213-214°C; IR (KBr) 3263, 3023, 2940, 2917, 1615, 1517, 1453, 1273, 1221, 1186, 1020, 1011, 831, 687. Anal. C 73.73, H 8.03, N 4.01, calcd. C 73.87, H 7.97, N 4.10.

EXAMPLE 13

1-(4-(tert-Butyldimethylsilyloxy)phenyl)-2-(3-phenylthio-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone

Following the procedure of Example 1, this product was prepared from 4-tert-butyldimethylsilyloxy-alpha-bromopropiophenone (1.25 g, 3.65 mmol), 3-phenylthio-8-azabicyclo[3.2.1.]octane (0.8 g, 3.65 mmol), and triethylamine (0.51 ml, 3.65 mmol) in ethanol (30 ml) with an overnight reflux. The product was flash chromatographed on silica gel (10% ethyl acetate/hexane elution); 0.889 g (51%); NMR 8.13 (d, J = 9Hz, 2H), 7.38 (m, 2H), 7.30-7.15 (m, 3H), 6.83 (d, J = 9Hz, 2H), 3.93 (q, J = 7Hz, 1H), 3.42-3.28 (m, 3H), 2.05-1.56 (m, 9H), 1.32 (d, J = 7Hz, 3H), 0.99 (s, 9H), 0.25 (s, 6H); IR 2940, 2840, 1600, 1390-1290 (br), 910.

EXAMPLE 14

Mixture of (1R*,2S*)- and (1S*,2S*)-1-(4-(tert-Butyldimethylsilyloxy)phenyl)-2-(3-phenylthio-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol

This product was prepared as in Example 2 with overnight stirring at ambient temperature from the product of the preceding Example (0.85 g, 1.77 mmol) and LiAlH₄ (0.153 g, 4.0 mmol) in tetrahydrofuran (24 ml). The product was isolated as a yellow oil (0.78 g, 91%) as a mixture of racemic title products.

-31-

EXAMPLE 15

(1S*,2S*)- and (1R*,2S*)-1-(4-Hydroxyphenyl)-2-
(3-phenylthio-8-azabicyclo[3.2.1]oct-8-yl-1-propanol

5 Title product of the preceding Example (0.78 g, 1.6 mmol) was desilylated according to the procedure of Example 3 with tetrabutylammonium fluoride (1.6 ml, 1.6 mmol; 1M in tetrahydrofuran) in a 5 minute reaction. The resulting mixture of racemates were separated by
10 silica gel flash chromatography (50% ethyl acetate/hexane elution). (1S*,2S*)-Title product eluted first; 0.133 g; NMR (DMSO d₆) 7.40-7.21 (m, 5H), 7.06 (d, J = 8.5Hz, 2H), 6.63 (d, J = 8.0 Hz, 2H), 4.35 (d, J = 5.0Hz, 1H), 3.54-3.40 (m, 2H), 3.35-3.29 (m, 2H), 2.70-2.62 (br t, 1H), 2.50 (m, 1H), 1.80-1.54 (m, 6H), 0.63 (d, J = 6.5Hz, 3H).

Continued elution gave (1R*,2S*)-title product: 0.102 g; NMR 7.45-7.40 (m, 2H), 7.32-7.22 (m, 3H), 7.15 (d, 2H), 6.76 (d, 2H), 4.80 (d, 1H), 3.60-3.52 (m, 2H),
20 3.51-3.38 (m, 1H), 2.80-2.72 (m, 1H), 2.00-1.55 (m, 8H), 0.68 (d, 3H). This product (80 mg) was converted to its HCl salt by dissolving in 15ml of ether, bubbling in dry HCl for 2 minutes and triturating the resulting oily solid with ether to yield 30 mg as a
25 white solid.

EXAMPLE 16

2-(4-Benzyl-4-hydroxypiperidino)-1-(4-(triisopropyl-
silyloxy)phenyl)-1-propanone

This product was prepared according to the
30 procedures of Example 1 from 4-hydroxy-4-benzylpiperidine (2.72 g, 14.22 mmol), 4-triisopropylsilyloxy-alpha-bromopropiophenone (5.48 g, 14.22 mmol), and

-32-

triethylamine (2.0 ml, 14.35 mmol) in ethanol (50 ml) with a reflux time of 17 hours to give 4.92 g (70%) of present, chromatographed title product as an orange oil; NMR 8.01 (d, J = 8.8Hz, 2H), 7.31-7.22 (m, 3H), 7.18-7.15 (m, 2H), 6.87 (d, J=8.8Hz, 2H), 4.03 (q, J = 6.7Hz, 1H), 2.72 (s, 2H), 2.68-2.57 (m, 3H), 2.45 (dt, 1H), 1.78-1.42 (m, 4H), 1.40-1.25 (m, 7H), 1.10 (d, J = 7Hz, 18H).

EXAMPLE 17

(1S*,2S*)- and (1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanol

Title product of the preceding Example (4.92 g, 9.33 mmol) was dissolved in ethanol (100 ml) and NaBH₄ (0.38 g, 10 mmol) was added all at once. After stirring overnight at ambient temperature, present (1S*,2S*)-title product was recovered by filtration, 2.11 g; NMR 7.46-7.17 (m, 7H), 6.84 (d, J = 7Hz, 2H), 4.18 (d, J = 11Hz, 1H), 2.86 (br t, 1H), 2.77 (s, 2H), 2.70-2.42 (m, 4H), 1.89-1.55 (m, 6H), 1.30-1.13 (m, 3H), 1.10 (d, J = 8.6 Hz, 18H), 0.75 (d, J = 6Hz, 3H).

The filtrate was concentrated and the residue dissolved in ethyl acetate, extracted with water (2x) and brine, dried (CaSO₄), concentrated to 2.33 g of a light yellow solid, and flash chromatographed on silica gel (2 x 6 inches, ethyl acetate/hexane gradient elution) to give first 1.4 g more of (1S*,2S*)-product, followed by 0.46 g of (1R*,2S*)-product; NMR 7.33-7.11 (m, 7H), 6.82 (d, J = 8.6Hz, 2H), 4.77 (d, J = 4Hz, 1H), 2.80-2.39 (m, 5H), 1.88-1.43 (m, 6H), 1.31-1.13 (m, 8H), 1.08 (d, J = 6.7Hz, 18H), 0.84 (d, J = 6.9Hz, 3H).

-33-

EXAMPLE 18

(1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-
(4-hydroxyphenyl)-1-propanol

5 By the method of Example 3, using ethyl
acetate/hexane gradient elution in chromatography,
(1R*,2S*)-title product of the preceding Example (0.46
g, 0.92 mmol) was converted to 0.24 g (74%) of present
title product as a monohydrate; mp 173-174°C; NMR (DMSO
10 d₆ with D₂O added) 7.21-7.12 (m, 5H), 7.04 (d, J =
7.6Hz, 2H), 6.64 (d, J= 8.6Hz, 2H), 4.64 (d, J= 8.6Hz,
1H), 2.59 (s, 2H), 2.59-2.49 (m, 5H--partially under
NMR solvent) 1.50-1.31 (m, 4H), 0.82 (d, J = 7Hz, 3H).
Anal. C 70.26, H 7.96, N 3.85; calcd. for monohydrate,
15 C 70.17, H 8.13, N 3.90.

EXAMPLE 19

2-(4-Benzyl-4-hydroxypiperidino)-1-
(4-fluoro-phenyl)-1-propanone

Title product, prepared as in Example 10 in 80%
20 yield, was recrystallized from ether, mp 119.5-120°C;
Anal. C 73.41, H 7.08, N 4.03, calcd. C 73.87, H 7.09,
N 4.10.

EXAMPLE 20

(1S*,2S*)- and (1R*,2S*)-2-(4-Benzyl-4-hydroxypiperi-
25 dino)-1-(4-fluorophenyl)-1-propanol

Title products, prepared as in Example 17, were
separated by flash chromatography on silica gel (ethyl
acetate-hexane then methanol-ethyl acetate gradient).
The 1S*,2S* product eluted first in 84% yield as a
30 solid which was recrystallized from ethanol/ether, mp
153.5-154.5°C. Anal. C 73.53, H 7.67, N 4.08, calcd. C
73.44, H 7.63, N 4.08.

-34-

The 1R*,2S* product, eluted second in 15% yield, was recrystallized from ethanol/ether, mp 145-146°C; Anal. C 73.18, H 7.59, N 4.06, calcd. C 73.44, H 7.63, N 4.08.

5

EXAMPLE 21

2-(3-Phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-
4-benzyloxyphenyl)-1-propanone

Title product, prepared following the procedure of Example 1 from 4-benzyloxy-alpha-bromopropiophenone, was obtained in 40-60% yield after silica gel flash chromatography; NMR 8.34 (d, 2H), 7.56-7.45 (m, 7H), 7.20 (d, 3H), 7.03 (d, 2H), 6.36 (s, 1H), 5.14 (s, 2H), 4.13 (q, 1H), 3.56-3.30 (m, 2H), 2.81 (t, 1H), 2.70-2.40 (m, 2H), 2.10-1.76 (m, 3H), 1.66 (m, 1H), 1.45 (d, 3H).

15

EXAMPLE 22

(1S*,2S*)-2-(3-Phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-benzyloxyphenyl)-1-propanol

20

Title product, prepared following the procedure of Example 3 with a 1.25 hour reaction time, was obtained in pure form by flash chromatography on silica gel, mp 145-148°C; Anal. C 81.69, H 7.46, N 3.02, calcd. C 81.97, H 7.57, N 3.19.

25

EXAMPLE 23

(1S*,2S*)-2-(3-Benzyl-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol

Title product of the preceding Example (0.23 g, 0.523 mmol) was dissolved in tetrahydrofuran (20 ml) and chilled to -78°C. Ammonia (30 ml) was condensed into the solution. Sodium (0.06 g, 2.6 mmol) was added

30

-35-

in three portions and a blue solution gradually formed. After 10 minutes the reaction was quenched with excess ammonium chloride and the mixture was allowed to warm to ambient temperature with evaporation of the ammonia. The residual mixture was concentrated, and the residue extracted with ethyl acetate. Filtration and concentration left 0.24 g of an oily solid which was flash chromatographed on silica gel (6 x 1 inch, ethyl acetate/hexane gradient elution followed by methanol flushing). This gave first recovered starting material followed by product (0.071 g). The product was further purified by recrystallization (ethyl acetate/hexane). A portion was spilled during this process but 0.005 g of white solid product was obtained as a 1:3 mixture of epimers of the benzyl group; NMR 7.30-7.10 (m, 7H), 6.72 (J = 8.5Hz) and 6.71 (J = 8.6Hz) (pair of overlapping d, total 2H), 4.11 (d, J = 8.6Hz, 1H), 3.45 (s, 1H), 3.31 and 3.24 (pair of s, 1H), 2.73 (J = 7.3Hz) and 2.48 (J = 7.2Hz) (pair of d, 2H), 2.61 (quintet, J = 7.6Hz, 1H), 2.11 (m, 1H), 1.86-1.17 (m, 10H), 0.81 (d, J = 6.7Hz, 3H). HRMS 352.2276, calcd. for MH⁺ 352.2278.

EXAMPLE 24

2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)-1-propanone

Title product, prepared from 4-chloro- α -bromopropiophenone, following the procedure of Example 10 in 72% yield, was purified by flash chromatography on

-36-

silica gel and recrystallized from ether, mp 135.5-136°C; Anal. C 70.11, H 6.70, N 3.85, calcd. C 70.48, H 6.76, N 3.91.

EXAMPLE 25

5 (1S*,2S*)- and (1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)-1-propanol

 Title products, prepared following the procedure of Example 17, were separated by the same chromatographic procedure. The 1S*,2S* product was obtained in 10 70% yield, mp 159.5-160.5°C (ethanol/ether); Anal. C 70.13, H 7.50, N 3.91, calcd. C 70.08, H 7.28, N 3.89.

 The 1R*,2S* product was obtained in 7% yield, mp 150.5-151.5°C (ethanol/ether); Anal. C 69.62, H 7.38, N 15 3.92, calcd. C 70.08, H 7.28, N 3.89.

EXAMPLE 26

 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)-1-ethanone

 Title product was prepared following the procedure of Example 10 from 4-chloro-alpha-bromoacetophenone in 20 76% yield; NMR 7.93 (d, J = 8.5Hz, 2H), 7.39 (d, J = 8.6Hz, 2H), 7.31-7.16 (m, 5H), 3.74 (s, 2H), 2.74 (s, 2H), 2.73-2.71 (m, 2H), 2.43 (dt, J = 11.5, 2.4Hz, 2H), 1.80 (dt, J = 12.7, 4.3Hz, 2H), 1.50 (br d, J = 13.8Hz, 25 2H).

EXAMPLE 27

 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)ethanol

 Title product, prepared from 4-chloro-alpha-bromoacetophenone following the procedure of Example 17 in 30 83% yield, was recrystallized from ethanol/ether, mp 151-152°C; NMR 7.34-7.18 (m, 9H), 4.67 (dd, J = 10.5,

-37-

3.5 Hz, 1H), 4.18 (br s, 1H), 2.89-2.86 (m, 1H), 2.76 (s, 1H), 2.68-2.47 (m, 3H), 2.41-2.31 (m, 2H), 1.73 (dq, J = 13.3, 4.4Hz, 2H), 1.58-1.50 (m, 2H), 1.24 (s, 1H).

5

EXAMPLE 28

2-(4-Benzyl-4-hydroxypiperidino)-1-
(4-fluorophenyl)-1-ethanone

Title product was prepared following the procedure of Example 10 in 59% yield from 4-fluoro-alpha-bromo-acetophenone; NMR 8.05-7.99 (m, 2H), 7.33-7.04 (m, 7H), 3.76 (s, 2H), 2.83-2.71 (m, 4H), 2.43 (dt, J = 11.5, 2.1Hz, 2H), 1.82 (dt, J = 12.7, 4.3Hz, 3H), 1.51 (br d, J = 11.5Hz, 2H).

10

EXAMPLE 29

2-(4-Benzyl-4-hydroxypiperidino)-1-
(4-fluorophenyl)-1-ethanol

Title product, prepared following the procedure of Example 17 in 85% yield, was recrystallized from ethanol/ether, mp 144.5-146°C; NMR 7.35-7.25 (m, 5H), 7.19 (d, J = 6.4Hz, 2H), 7.01 (t, J = 8.7Hz, 2H), 4.67 (dd, J = 10.5, 3.5Hz, 1H), 4.18 (br s, 1H), 2.88 (br d, J = 11.2Hz, 1H), 2.76 (s, 2H), 2.68-2.31 (m, 5H), 1.81-1.66 (m, 2H), 1.58-1.50 (m, 2H), 1.28 (s, 1H).

15

20

25

30

-38-

EXAMPLE 30

Endo-1-(4-(Triisopropylsilyloxy)phenyl)-
2-(3'-phenylspiro[8-azabicyclo[3.2.1]octane-
3,2'-oxirane]-8-yl)-1-propanone

5

Title product of Preparation 13 below (0.72 g, 3.34 mmol), title product of Preparation 10 below (1.29 g, 3.35 mmol), and potassium carbonate (0.93 g, 6.7 mmol) were combined in tetrahydrofuran (80 ml), refluxed for 30 hours, cooled and filtered through diatomaceous earth. The filtrate was concentrated and chromatographed on silica gel (ethyl acetate/hexane gradient elution) to give 0.77 g (44%) of title product as a mixture of diastereomers. The epoxide protons were observed at delta 3.65 and 3.60 ppm in the NMR spectrum.

10

15

The corresponding exo isomer was prepared in like manner from the other isomer of Preparation 13 in 37% yield. The epoxide protons in the mixture of diastereomeric products were observed at 3.80 and 3.86 ppm in the NMR spectrum.

20

EXAMPLE 31

Endo- and exo-(1S*,2S*) and (1R*,2S*)-1-(4-(Triisopropylsilyloxy)phenyl)-2-(3'-phenylspiro[8-azabicyclo-
[3.2.1]octane-3,2'-oxirane]-8-yl)-1-propanol

25

A mixture of present endo title products was prepared from endo title product of the preceding Example in 82% yield by the procedure of Example 17. Flash chromatography gave pure, faster running (1S*, 2S*)-isomer; NMR 7.34-7.23 (m, 5H), 7.17 (d, J = 8.5Hz, 2H), 6.82 (d, J = 8.5Hz, 2H), 4.02 (d, J = 8Hz, 1H), 3.65 (s, 1H), 3.45 (br s, 1H), 3.28 (br s, 1H), 2.65

30

-39-

(quintet, $J = 7.2\text{Hz}$, 1H), 2.54 (dd, $J = 13.8$, 3.2Hz, 1H), 2.15 (q, $J = 8.6\text{Hz}$, 2H), 1.93-1.72 (m, 4H), 1.40 (d, $J = 13.8\text{Hz}$, 2H). Slower running ($1R^*$, $2S^*$)-isomer, which shows a characteristic NMR signal at 4.81 ppm (br s, 1H) was obtained as a mixture with the ($1S^*$, $2S^*$)-isomer.

The corresponding exo isomers were prepared in like manner from the exo-isomer of the preceding Example in 82% yield as a 3:1 mixture of ($1S^*$, $2S^*$) and ($1R^*$, $2S^*$) isomers. The epoxide protons were seen at 3.86 and 3.82 ppm in the NMR spectrum.

EXAMPLE 32

Endo- ($1S^*$, $2S^*$)-1-(4-Hydroxyphenyl)-2-(3'-phenylspiro[8-azabicyclo-[3.2.1]octane-3,2'-oxirane]-8-yl)-1-propanol

By the method of Example 3, endo- ($1S^*$, $2S^*$)-title product of the preceding Example was converted to present title product in 62% yield; mp 204.5-205°C (chloroform/hexane); NMR 7.32-7.25 (m, 5H), 7.17 (d, $J = 8.4\text{Hz}$, 2H), 6.73 (d, $J = 6.6\text{Hz}$, 2H), 5.25 (br s, 1H), 4.01 (d, $J = 8.2\text{Hz}$, 1H), 3.66 (s, 1H), 3.47 (br s, 1H), 3.31 (br s, 1H), 2.65-2.54 (m, 2H), 2.16 (d, $J = 8\text{Hz}$, 2H), 1.89-1.73 (m, 3H), 1.44 (br d, $J = 13.9\text{Hz}$, 1H), 1.24 (br d, $J = 14\text{Hz}$, 1H), 0.83 (d, $J = 6.7\text{Hz}$, 3H).

EXAMPLE 33

Endo- ($1S^*$, $2S^*$)-2-(3-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanol

The endo- ($1S^*$, $2S^*$)/($1R^*$, $2S^*$) mixture of Example 31 (0.19 g, 0.36 mmol) was dissolved in tetrahydrofuran (20 ml) and chilled to -78°C. Ammonia (30 ml) was condensed into the solution and sodium metal (0.08 g)

-40-

was added in small chunks over 1 hour. At this time the mixture turned deep blue. The reaction was stirred 10 minutes longer, then quenched with solid NH_4Cl . The ammonia was allowed to evaporate, the residual mixture was partitioned between ethyl acetate and water, and the aqueous layer was extracted with fresh ethyl acetate. The combined organic layers were washed with brine, dried over CaSO_4 and concentrated to give 0.18 g (95%) of a light yellow oil, which was purified by flash chromatography on silica gel (ethyl acetate/hexane gradient elution) to give 0.1 g of colorless oil which was the (1S*,2S*)-title product; NMR 7.33-7.25 (m, 3H), 7.18 (d, J = 8.3Hz, 4H), 6.84 (d, J = 8.4Hz, 2H), 4.09 (d, J = 7.5Hz, 1H), 3.42 (br s, 1H), 3.13 (br s, 1H), 2.70-2.58 (m, 3H), 2.11-1.91 (m, 4H), 1.73-1.51 (m, 4H), 1.30-1.16 (m, 5H), 1.09 (d, J = 6.9Hz, 18H), 0.86 (d, J = 6.7Hz, 3H).

EXAMPLE 34

Endo-(1S*,2S*)-2-(3-Benzyl-3-hydroxy-8-azabicyclo-[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol

By the procedure of Example 3, title product of the preceding Example was converted to present title product in 38% yield after flash chromatography and recrystallization from ethyl acetate/hexane; mp 162-163°C; ^{13}C -NMR 156.97, 138.80, 135.86, 131.73, 129.11, 128.70, 127.07, 115.58, 76.09, 71.74, 64.64, 62.36, 54.62, 52.97, 45.82, 45.68, 29.28, 28.85, 14.50.

By the procedure of the preceding Example, the title product of Example 32 is converted to the same product.

-41-

EXAMPLE 35

Exo-(1S*,2S*)- and (1R*,2S*)-1-(4-hydroxyphenyl)-
2-(3'-phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-
oxirane]-8-yl)-1-propanol

5

By the procedure of Example 3, the exo-(1S*,2S*)/
(1R*,2S*) mixture of Example 31 was converted to a
mixture of present title products in 93% yield. The
(1S*,2S*) isomer was separated by flash chromatography
and recrystallized from ether/hexane, mp 115-117°C.
The (1R*,1S*) isomer, obtained as a minor component
(about 25%) in later fractions of the chromatography,
was also recrystallized from ether/hexane, mp
107-110°C.

10

15

EXAMPLE 36

1-(4-(Triisopropylsilyloxy)phenyl)-2-(4-hydroxy-4-
phenylpiperidino)-1-propanone

20

By the procedure of Example 1, 4-hydroxy-4-phenyl-
piperidine was converted to present title product in
37% yield as a clear oil; NMR 8.03 (d, J = 8.5Hz, 2H),
7.47 (d, J = 8Hz, 2H), 7.33 (t, J = 7.5Hz, 2H),
7.26-7.24 (m, 1H), 6.89 (d, J = 8.5Hz, 2H), 4.08 (q, J
= 7.5Hz, 1H), 2.90-2.60 (m, 2H), 2.25-2.10 (m, 2H),
1.85-1.75 (m, 2H), 1.65-1.55 (m, 2H), 1.32-1.22 (m,
6H), 1.10 (d, J = 7Hz, 18H).

25

EXAMPLE 37

(1S*,2S*)-1-(4-(Triisopropylsilyloxy)phenyl)-2-
(4-hydroxy-4-phenylpiperidino)-1-propanol

30

By the procedure of Example 17, title product of
the preceding Example was converted to present title
product in 87% yield; mp 148-151°C; NMR 7.52 (d, J =
7Hz, 2H), 7.38 (t, J = 7Hz, 2H), 7.30-7.25 (m, 1H),
7.19 (d, J = 8.5Hz, 2H), 6.84 (d, J = 8.5Hz, 2H), 4.23

-42-

(d, J = 9.5Hz, 1H), 3.13-3.02 (m, 1H), 2.80-2.58 (m, 3H), 2.30-2.08 (m, 2H), 1.90-1.78 (m, 2H), 1.29-1.17 (m, 3H), 1.09 (d, J = 7Hz, 18H), 0.79 (d, J = 6.5Hz, 3H).

5

EXAMPLE 38

(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenyl-piperidino)-1-propanol

Title product, prepared following the procedure of Example 3 from title product of the preceding Example in 65% yield, was recrystallized from ethanol; mp 202-204°C; Anal. C 71.95, H 8.09, N 4.26, calcd. for 0.5 C₂H₅OH, C 71.97, H 8.05, N 4.00.

10

EXAMPLES 39-76

Using the methods of the preceding Examples, the following additional compounds were prepared, specifying yield to purified material in the final step:

15

39. 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)ethanol; 42%; mp 98-99°C (from ethanol).

20

40. (1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-methoxyphenyl)-1-propanol; 36%; mp 145.5-146°C (from ethanol/ether).

25

41. (1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-pentanol; 55%; mp 158-159°C (from ethanol/ether).

42. (1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-pentanol; 37%; mp 156-157°C (from ether).

30

-43-

43. (1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-butanol; 53%; mp 190-191°C (from ethanol).
- 5 44. (1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-methoxyphenyl)-1-butanol; 61%; mp 143-144°C (purified by flash chromatography on silica gel using ethyl acetate/hexane gradient elution).
- 10 45. 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-cyanophenyl)ethanol; 52%; mp 142-143°C (from ethanol/ether/hexane).
46. 2-(4-Benzyl-4-hydroxypiperidino)-1-(2-hydroxyphenyl)ethanol; 43%; mp 172-173.5°C (from ethanol).
- 15 47. 2-(4-Benzyl-3-hydroxypiperidino)-1-(3-hydroxyphenyl)ethanol; 76%; mp 198-199°C (from ethanol).
48. 1-(4-Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 63%; mp 155.5-157°C (from ethanol/ether).
- 20 49. (1S*,2S*)-2-(4-(4-chlorophenyl)-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-propanol; 58%; mp 204-206°C (from ethyl acetate).
50. 2-(4-Hydroxy-4-phenylpiperidino)-1-(2-thienyl)ethanol; 54%; mp 167-168°C (from ethanol).
- 25 51. (1S*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(2-thienylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol; 38%; mp 127.5-129°C (from ethyl acetate/hexane).
52. (1R*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(2-thienylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol; 19%; mp 141-142.5°C (from ethyl acetate).
- 30

-44-

53. (1S*,2S*)-Exo-2-(3-(4-chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol; 84%; mp 181-182.5°C (from ethyl acetate).
- 5 54. (1R*,2S*)-Exo-2-(3-(4-chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol; 94%; mp 154-156°C (from ethyl acetate/hexane).
- 10 55. (1S*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(4-methoxyphenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol; 55%; mp 118-119°C (from ethyl acetate/hexane).
- 15 56. (1R*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(4-methoxyphenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol; 37%; mp 72-75°C (flash chromatography on silica gel using ethyl acetate/hexane gradient elution and hexane trituration).
- 20 57. 1-(4-Trifluoromethylphenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 34%; mp 152-153°C (from ethanol/ether).
- 20 58. 1-(4-Acetamidophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 34%; mp 217.5-218°C (from ethanol).
- 25 59. (1S*,2S*)-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(2-phenylethyl)piperidino]-1-propanol; 51%; mp 200-201°C (from ethyl acetate).
- 25 60. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-(3-phenylpropyl)piperidino]-1-propanol; 46%; mp 200.5-201°C (from ethyl acetate).
- 30 61. (1S*,2S*)-2-[4-(4-Fluorophenyl)-4-hydroxypiperidino]-1-(4-hydroxyphenyl)-1-propanol; 37%; mp 197-198°C (from ethyl acetate).

-45-

62. 1-(4-Cyanophenyl)-2-(4-hydroxy-4-phenyl-piperidino)ethanol; 51%; mp 140-140.5°C (from ethanol/ether).
- 5 63. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-(4-methylphenyl)piperidino]-1-propanol; 41%; mp 188-189°C.
64. 1-(4-Carbamoylphenyl)-2-(4-hydroxy-4-phenyl-piperidino)ethanol; 23% mp 213.5-215°C (from ethanol).
- 10 65. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-(3-endo-hydroxy-3-phenyl-8-azabicyclo[3.2.1]octan-8-yl)-1-propanol; 60%; 216-217°C (from ethanol/ether).
66. (1S*,2S*)-1-(4-Fluorophenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 44%; mp 177-179°C (from ethanol).
- 15 67. (1R*,2S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 25%; mp 152-155°C (from ethanol).
68. (1S*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-1-phenyl-1-propanol; 50%; mp 149-152°C (from ethyl acetate/hexane).
- 20 69. (1S*,2S*)-1-(4-Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 38%; mp 192-194°C (from ethanol).
- 25 70. 1-(4-Aminophenyl)-2-(4-hydroxy-4-phenyl-piperidino)ethanol; 47%; mp 156.5-158°C (from ethyl acetate/ether).
71. (1S*,2S*)-2-(3-Benzyl-3-hydroxypyrrolidino)-1-(4-hydroxyphenyl)-1-propanol; 71%; mp 134-136°C.
- 30 72. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-(3-hydroxy-3-phenylpyrrolidino)-1-propanol; 56%; mp 74-78°C.

-46-

73. (1S*,2S*)-1-(4-Chlorophenyl)-2-[4-hydroxy-4-(2-phenylethyl)piperidino]-1-propanol; 33%; mp 152-154°C (from ethanol).

5 74. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-(4-Phenylbutyl)piperidino]-1-propanol; 44%; mp 191-192°C (from ethanol).

75. 1-(4-Carboxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 98%; mp 254.5-255°C (from H₂O).

10 76. 2-(4-Hydroxy-4-phenylpiperidino)-1-[4-(methoxycarbonyl)phenyl]ethanol; 57%; mp 138.5-139.5°C (from ethanol/ether).

EXAMPLE 77

15 (R-1-(4-Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol

4-Hydroxy-4-phenylpiperidine (177 mg, 1 mmol) was dissolved in dry tetrahydrofuran (13 mL) and chilled to -15°C with stirring and under a nitrogen atmosphere. Butyllithium (0.8 ml, 2 mmol, 2.5N) was added dropwise over 3 minutes. (-)-R-1-(4-chlorophenyl)ethylene oxide [155 mg, 1 mmol; J. Am. Chem. Soc. 109, 7925 (1987); J. Org. Chem. 53, 2861 (1988)] was dissolved in 1 mL tetrahydrofuran and added to the cold reaction with a 1 mL rinse. The mixture was warmed to ambient temperature and finally refluxed overnight. The mixture was cooled to room temperature and quenched with solid NaHCO₃. The crude reaction was directly chromatographed on silica gel using on ethyl acetate-hexane gradient elution. The product containing fractions were carefully rechromatographed on silica gel with 50% ethyl acetate-hexane elution to

-47-

give 112 mg (33%) of product as an oily foam. Trituration with ether-hexane gave 15.2 mg of cream colored product which had mp 110-113°C; $[\alpha]_D = -18^\circ$.

(S)-1-(4-(Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol, having the same physical properties except for sign of rotation was prepared in the same manner from (+)-S-1-(4-chlorophenyl)ethylene oxide.

EXAMPLE 78

Enantiomeric (1S,2S)- and (1R,2R)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanols

(+)-Tartaric acid (300 mg, 2 mmol) was dissolved in 30 mL warm methanol. Racemic 1S*,2S*-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidinyl)propanol (655 mg, 2 mmol) was added all at once. With stirring and gentle warming a colorless homogeneous solution was obtained. Upon standing at ambient temperature 24 hours, 319 mg (66%) of a fluffy white precipitate was obtained. This product was recrystallized from methanol to give 263 mg of the (+)-tartrate salt of dextrorotatory title product as a white solid; mp 206.5-207.5°C; $[\alpha]_D = -36.2^\circ$. This salt (115 mg) was added to 50 ml of saturated NaHCO_3 . Ethyl acetate (5 ml) and the mixture was vigorously stirred 30 minutes. The aqueous phase was repeatedly extracted with ethyl acetate. The organic layers were combined and washed with brine, dried over calcium sulfate, and concentrated. The tan residue was recrystallized from ethyl acetate-hexane to give 32 mg (39%) of white,

-48-

dextrorotatory title product; mp 203-204°C; $[\alpha]_D = +56.9^\circ$. Anal. Calcd. for $C_{20}H_{25}NO_3$: C, 73.37; H, 7.70; N, 4.28. Found: C, 72.61; H, 7.45; N, 4.21.

5 The filtrate from the (+)-tartrate salt
preparation above was treated with 100 ml saturated
aqueous $NaHCO_3$ and extracted well with ethyl acetate.
The combined organic extracts were washed with brine,
dried over calcium sulfate and concentrated to give
10 380 mg of recovered starting material (partially
resolved). This material was treated with (-)-tartaric
acid (174 mg) in 30 mL of methanol as above. After
standing for 24 hours, filtration gave 320 mg (66%) of
product which was further recrystallized from methanol
15 to produce 239 mg the (-)-tartrate salt of levorotatory
title product; mp 206.5-207.5°C; $[\alpha]_D = +33.9^\circ$.
The latter was converted to levorotatory title product
in the manner above in 49% yield; mp 204-205°C;
[α]_D = -58.4°. Anal. Found: C, 72.94; H, 7.64; N,
20 4.24.

EXAMPLE 79

(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(1,2,3,6-
tetrahydro-4-phenylpyrido)-1-propanol

By the methods of Examples 1, 2 and 3,
25 4-(triisopropylsilyloxy)-alpha-bromopropiophenone and
1,2,3,6-tetrahydro-4-phenylpyridine were converted to
present title product in 14% yield in the last step; mp
208-211°C (dec.).

30

-49-

PREPARATION 18-(2,2,2-Trichloroethoxycarbonyl)-3-phenyl-
methylene-8-azabicyclo[3.2.1]octane

5 A solution of benzyltriphenylphosphonium chloride (13.26 g, 34.1 mmol) in tetrahydrofuran (400 ml) was chilled to -78°C and butyl lithium (13.6 ml of 2.5M in hexanes, 34 mmol) was added. This resulted in a heterogeneous orange mixture which was stirred 5 minutes at -78°C and then warmed to 0°C. The solution
10 became nearly homogeneous red and N-2,2,2-trichloroethoxycarbonyltropinone (7.1 g, 23.3 mmol; Montzka et al., Tetrahedron Letters, vol, 14, p. 1325, 1974) was added in tetrahydrofuran (20 ml with a 20 ml rinse).
15 The reaction was refluxed 4 days, cooled, and filtered. Concentration of the filtrate left a viscous brown oil. Flash chromatography on silica gel (3 x 6 inches) using first hexane and then an ethylacetate/hexane gradient gave 7.87 g of white solid product (74%); mp 88-89°C,
20 ir (KBr) 3437, 2958, 1700, 1445, 1425, 1321, 1125, 711. Anal. C 54.89, H 4.82, N 3.77, calcd. C 54.49, H 4.84, N 3.74.

PREPARATION 23-Phenylmethylene-8-azabicyclo[3.2.1]octane

25 A mixture of title product of the preceding Preparation (1.0 g, 2.67 mmol), zinc dust (0.88 g, 13.46 mmol), and acetic acid (50 ml) was stirred overnight. The reaction was then heated at 70°C for 22 hours, then cooled and concentrated. The residue was partitioned
30 between ether/ethyl acetate and saturated NaHCO₃, and the mixture stirred 30 minutes and then filtered over

-50-

diatomaceous earth. The aqueous phase was separated and further extracted with ethyl acetate (2x). The combined organic layers were washed with water and brine, dried (CaSO_4) and concentrated to leave 0.5 g of light yellow oil. Further purification was effected by taking the oil up in 10% HCl. This acid solution was extracted with ethyl acetate (2x). The acidic layer was neutralized over ice with sodium hydroxide and back extracted into ethyl acetate. This organic layer was dried (CaSO_4) and concentrated to leave 0.24 g (48%) of light yellow oil; NMR 7.24 (m, 2H), 7.13 (d, $J = 6.6\text{Hz}$, 3H), 6.28 (s, 1H), 3.52 (br d, $J = 28.2\text{Hz}$, 2H), 2.56 (t, $J = 15.4\text{Hz}$, 3H), 2.26 (d, $J = 14.7\text{Hz}$, 1H), 2.12 (d, $J = 13.9\text{Hz}$, 1H), 1.64 (m, 3H), 1.40 (m, 1H).

Alternatively, the product was converted to its HCl salt by treating an acetone solution with HCl gas.

PREPARATION 3

4-(tert-Butyldimethylsilyloxy)propiophenone

4-Hydroxypropiophenone (15 g, 100 mmol) and imidazole (17 g, 250 mmol) were dissolved in dimethylformamide (50 ml). tert-Butyldimethylsilyl chloride (19.6 g, 130 mmol) in dimethylformamide (40 ml) was added dropwise at ambient temperature. The mixture was stirred 18 hours, then diluted with water (300 ml) and extracted with ether (4 x 200 ml). The combined ether layers were washed with 1M LiCl and brine, dried (CaSO_4), concentrated to an oily solid, flash chromatographed on silica gel using 1:10 ethylacetate:hexane as eluant to yield 26 g of title product which was further purified by short path

-51-

distillation to yield 23.2 g (88%) of purified title product as a hygroscopic white solid; mp 30-31°C; NMR 7.76 (d, J = Hz, 2H), 6.74 (d, J = Hz, 2H), 2.82 (q, J = Hz, 2H), 1.09 (t, J = Hz, 3H), 0.87 (s, 9H), 0.11 (s, 6H).

PREPARATION 4

4-(tert-Butyldimethylsilyloxy)-alpha-bromopropiophenone
4-(tert-Butyldimethylsilyloxy)propiphenone (20 g, 75.8 mmol) was dissolved in acetic acid (300 ml) and bromine (3.9 ml, 75.8 mmol in 30 ml of acetic acid) was added dropwise. The orange color of bromine persisted for about 1 minute and then the reaction rapidly decolorized as the bromine was added. The reaction was stirred 1 hour further, then concentrated and the residue flash chromatographed on silica gel (hexane elution) to give 7.12 g of oily product; NMR 7.92 (d, J = 9Hz, 2H), 6.86 (d, J = 9Hz, 2H), 5.22 (q, J = 6.5 Hz, 1H), 1.85 (d, J = 6.5Hz, 3H), 0.96 (s, 9H), 0.22 (s, 6H). ¹³C NMR 76.73, 59.55, 40.47, 38.59, 37.68, 25.42.

PREPARATION 5

O-Methanesulfonyltropine

Tropine (14.2 g, 100 mmol) was dissolved in CH₂Cl₂ (210 ml) and triethylamine (23 ml, 160 mmol) was added. Methanesulfonyl chloride (9.3 ml, 120 mmol) was added rapidly dropwise which caused the methylene chloride solution to reflux gently. The mixture was stirred one hour further; then extracted with cold 0.5 molar sodium hydroxide, water, and brine, dried by filtration through phase separating paper and concentrated to yield 13.8 g (65%) of title product as a yellow solid;

-52-

NMR 4.88 (t, J = 5Hz, 1H), 3.10-3.05 (m, 2H), 2.94 (s, 3H), 2.22 (s, 3H), 2.20-2.10 (m, 2H), 2.02-1.88 (m, 6H).

PREPARATION 6

5

3-Phenylthio-8-methyl-8-azabicyclo[3.2.1]octane

NaH (60% in oil; 2.77 g, 69 mmol) was washed with hexane (3x) and then suspended in tetrahydrofuran (300 ml). Thiophenol (6.5 ml, 63 mmol) in tetrahydrofuran (25 ml) was added dropwise over 5 minutes. The milky white suspension which formed, with hydrogen evolution, was stirred 10 minutes and then O-methanesulfonyltropine (13.8 g, 63 mmol in 25 ml of tetrahydrofuran) was added all at once. The mixture was refluxed overnight, cooled and filtered through diatomaceous earth with ether wash. The filtrate was diluted with ethyl acetate and washed with cold 1M NaOH, water, and brine, dried (CaSO₄) and concentrated to yield 11.48 g (78%) of title product as a yellow solid; NMR 7.50-7.18 (m, 5H), 3.32-3.21 (m, 1H), 3.15-3.09 (m, 2H), 2.25 (s, 3H), 2.02-1.94 (m, 2H), 1.79-1.72 (m, 4H), 1.60-1.51 (m, 2H); ¹³C NMR 134.8, 132.3, 128.8, 126.9, 61.16, 39.21, 38.38, 37.72, 26.42.

20

PREPARATION 7

25

3-Phenylthio-8-(2,2,2-trichloroethoxycarbonyl)-8-azabicyclo[3.2.1]octane

Title product of the preceding Preparation (11.48 g, 49.3 mmol) and K₂CO₃ (0.75 g, 5.4 mmol) were mixed with benzene (200 ml) and 2,2,2-trichloroethyl chloroformate (7.5 ml, 54.4 mmol) was added rapidly. The reaction was refluxed 2 hours, cooled, filtered,

30

-53-

and concentrated. The orange oily residue was dissolved in CH_2Cl_2 , washed with saturated NaHCO_3 and then brine, dried (CaSO_4) and concentrated. The residue was purified by flash chromatography on silica gel (hexane and then 5% ethyl acetate/hexane elution) to give first unreacted thiophenol from the previous reaction and then title product as a yellow oil (13 g, 67%); NMR 7.42-7.23 (m, 5H), 4.72 (AB q, $J = 12\text{Hz}$, 2H), 4.35-4.30 (m, 4H), 2.73 (heptet, $J = 6\text{Hz}$, 1H), 2.05-1.68 M, 6H). The oil was solidified by trituration with hexane; mp 83-84.5°C; Anal. C 48.47, H 4.58, N 3.49, calcd. C 48.68, H 4.60, N 3.55.

PREPARATION 8

3-Phenylthio-8-azabicyclo[3.2.1]octane

Title product of the preceding Preparation (13.0 g, 33 mmol) was dissolved in acetic acid (400 ml) and zinc dust (11 g, 168 mmol) was added. The mixture was heated to 100°C overnight, then concentrated and the residue partitioned between CH_2Cl_2 and saturated NaHCO_3 . The resulting emulsion was cleared by filtration through diatomaceous earth. The phases were separated and the organic layer was dried through phase separating filter paper and concentrated to yield 6.1 g (84%) of title product as a yellow oil which solidified on standing; NMR 7.38-7.36 (m, 2H), 7.29-7.20 (m, 3H), 3.52 (s, 2H), 3.36 (heptet, $J = 6\text{Hz}$, 1H), 1.94-1.54 (m, 8H); ^{13}C NMR 134.0, 132.43, 128.83, 127.06, 54.93, 40.81, 39.01, 28.98.

-54-

PREPARATION 94-(Triisopropylsilyloxy)propio-phenone

By the method of Preparation 3, 4-hydroxypropio-
phenone and triisopropylsilyl chloride were converted
to present title product as a clear oil in 100% yield;
NMR 7.87 (d, J = 8.5Hz, 2H), 6.89 (d, J = 8.5Hz, 2H),
2.94 (q, J = 7Hz, 2H), 1.32-1.15 (m, 3H), 1.20 (t, J =
7Hz, 3H), 1.09 (d, J = 7Hz, 18H).

PREPARATION 104-(Triisopropylsilyloxy)-alpha-bromopropiophenone

Title product of the preceding Preparation (60.63
g, 198 mmol) was dissolved in CCl₄ (1100 ml) and a
solution of bromine (11 ml, 210 mmol in 60 ml CCl₄)
added dropwise. After a portion of the bromine
solution was added without any noticeable decoloration
after 15 minutes, acetic acid (1.0 ml) was added in two
portions. The solution decolorized within 20 minutes
and the addition was completed fairly rapidly. The
mixture was stirred 15 minutes more; then the volatile
HBr was partially removed with the aid of a nitrogen
stream. The reaction was poured onto water (600 ml)
and the phases were separated. The organic layer was
washed with water, saturated NaHCO₃, water, and brine,
dried (CaSO₄), and concentrated to leave 76.2 g (100%)
of present title produced as a clear yellow oil; NMR
7.94 (d, J = 9Hz, 2H), 6.91 (d, J = 9Hz, 2H), 5.24 (q,
J = 6.5Hz, 1H), 1.87 (d, J = 6.5Hz, 2H), 1.33-1.17 (m,
3H), 1.10 (d, J = 7Hz, 18H).

-55-

PREPARATION 114-Fluoro-alpha-bromopropiophenone

5 Title product, prepared as in Preparation 4 in 86% yield after distillation, was recrystallized from ethanol to afford a white crystalline solid; mp 33-34°C. Anal. C 46.67, H 3.38, calcd. C 46.78, H 3.49.

PREPARATION 124-Chloro-alpha-bromopropiophenone

10 The product, prepared following the procedure of Preparation 10 in 98% yield, was recrystallized from ethanol, mp 78-79°C; Anal. C 43.74, H 3.17, calcd. C 43.67, H 3.26.

PREPARATION 13

15 Endo- and Exo-8-(2,2,2-Trichloroethoxycarbonyl)-3' phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-oxirane]

The title product of Preparation 2 (5.0 g, 13.34 mmol) was dissolved in CH_2Cl_2 (80 ml) and
20 m-chloroperbenzoic acid (2.71 g, 13.35 mmol, 85% purity) added. After stirring at ambient temperature overnight, the mixture was extracted with saturated NaHCO_3 , then with water and brine, dried through phase separating paper, and concentrated to give 5.3 g of a
25 glassy yellow oil which was chromatographed on silica gel (ethyl acetate/hexane gradient elution). Recovered starting material was eluted first followed by a fast moving endo epoxide product (2.23 g, 42.8%); mp 78-79°C; Anal. C 52.75, H 4.44, N 3.20, calcd. C 52.26, H 4.64, N 3.59; and finally by a slow moving exo
30 epoxide product (2.32 g, 44.5%); mp 107-108°C; Anal. C 52.34, H 4.40, N 3.54, calcd. as for endo isomer.

-56-

PREPARATION 14

Endo- and exo- 3'-Phenylspiro[8-azabicyclo[3.2.1]-
octane-3,2'-oxirane]

5 The fast moving endo product of the preceding
Example (1.55 g, 3.97 mmol) was dissolved in
tetrahydrofuran (30 ml) and zinc powder (9.3 g, 142
mmol) and 1 molar monopotassium phosphate (10 ml) were
added. After stirring overnight, the mixture was
10 diluted with water (10 ml), the pH adjusted to 10-11
with NaCO_3 and filtered over diatomaceous earth with
ethyl acetate and water wash. The aqueous layer in the
combined filtrate and washes was separated and washed
with fresh ethyl acetate. The combined organic layers
15 were washed with brine, dried (CaSO_4) and stripped to
yield 0.85 g (100%) of endo-title product as a yellow
oil. Short path distillation (110-115°C bath
temperature, 0.5 mm) gave endo title product as a clear
colorless oil; NMR 7.34-7.23 (m, 5H), 3.63-3.60 (m,
20 2H), 3.55 (m, 1H), 2.36 (dd, $J = 14.1, 3.5\text{Hz}$, 1H),
2.17-2.12 (m, 2H), 1.83-1.81 (m, 2H), 1.70-1.61 (m,
2H), 1.42 (dt, $J = 11.9, 2.2\text{Hz}$, 1H), 1.18 (dt, $J =$
14.5, 2.3Hz, 1H). HRMS 215.1301, calcd. 215.1308.

25 By the same method, the slow moving isomer of the
preceding Preparation was converted to the
corresponding exo isomer in 96% yield, purified by
short path distillation (110-125°C bath temperature,
0.8 mm); mp 114.5-116°C. Anal. C 77.97, H 8.05, N
6.44, calcd. C 78.10, H 7.96, N 6.51.


30

-57-

CLAIMS

1. A compound of the formula

5



10

wherein

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

15


Q is S or CH=CH;

X is hydrogen, (C₁-C₃)alkyl, halo, OR¹, OCOR¹, CO₂R¹, SR¹, NHR¹, NHCOR¹, CONH₂ or CN;


R¹ is hydrogen or (C₁-C₃)alkyl;

Y and Y¹ are taken together and are

20



25




30

-58-


Y and Y¹ are taken separately and
Y is hydrogen or OH, and Y¹ is

5



10

Y is hydrogen and Y^1 is



15

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

Q^1 is independently a value of Q as defined above;

20

x^1 is independently a value of X as defined above;

and

Z is O, S, SO or SO₂; or


a pharmaceutically acceptable acid addition salt thereof.

25

2. A compound of claim 1 wherein R is methyl having 1S*,2S* relative stereochemistry:

30

-59-



5

3. A compound of claim 1 wherein Q is CH=CH and X is 4-hydroxy.


10

4. A compound of claim 2 wherein Q is CH=CH and X is 4-hydroxy.

5. The compound of claim 4 wherein Y and Y¹ are taken together and are phenylmethylene.

15

6. The compound of claim 4 wherein Y and Y¹ are taken together and are



20

7. A compound of claim 4 wherein Y and Y¹ are taken separately.

8. The compound of claim 7 wherein Y is H and Y¹ is phenylthio.

25

9. The compound of claim 7 wherein Y is H and Y¹ is 4-chlorophenylthio.


10. The compound of claim 7 wherein Y is H and Y¹ is 2-thienylthio.

30

11. A compound of claim 7 wherein Y is H or OH and Y¹ is benzyl.

-60-


12. A compound of the formula



10

wherein

D is



R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

Q is S or CH=CH;


20

X is hydrogen, (C₁-C₃)alkyl, halo, OR¹, OCOR¹, CO₂R¹, SR¹, NHR¹, NHCOR¹, CONH₂ or CN;

R¹ is hydrogen or (C₁-C₃)alkyl;


Y² and Y³ are taken together and are

25



30

-61-




; or

5


Y^2 and Y^3 are taken separately, and Y^2 is OH and Y^3 is

10



;

15 Y^9 is



;

20

Q^1 is independently a value of Q as defined above;

X^1 is independently a value of X as defined above;

n is 0, 1, 2 or 3; and

m is 0, 1, 2, 3 or 4; or


25

a pharmaceutically-acceptable acid addition salt thereof.


13. A compound of claim 12 wherein Q is CH=CH, X is substituted at the 4-position of the phenyl ring and is hydroxy, fluoro or chloro, D is

30

-62-



or



5


and Y^2 and Y^3 are taken separately.

14. A compound of claim 13 wherein R is hydrogen, X is 4-fluoro or 4-chloro, and Y^3 is benzyl, 2-phenylethyl or 3-phenylpropyl.

10

15. A compound of claim 13 wherein R is methyl having 1S*,2S* relative stereochemistry:

15



20

16. A compound of claim 15 wherein X is 4-hydroxy and Y^3 is benzyl.

17. A compound of claim 15 wherein X is 4-fluoro and Y^3 is benzyl.

18. A compound of claim 15 wherein X is 4-chloro and Y^3 is benzyl.

25

19. A compound of claim 15 wherein X is 4-hydroxy and Y^3 is phenyl or 4-chlorophenyl.


20. A compound of claim 15 wherein X is 4-hydroxy and Y^3 is 2-phenylethyl.

30

21. A compound of claim 15 wherein X is 4-hydroxy and Y^3 is 3-phenylpropyl.

-63-

22. A compound of the formula



10

wherein

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

Q and Q¹ are each independently S or CH=CH;

15

X and X¹ are each independently H, (C₁-C₃)alkyl, halo, OR¹, OCOR¹, COOR¹, SR¹, NHR¹, NHCOR¹, CONH₂ or CN;

R¹ is H or (C₁-C₃)alkyl;

Y⁴ is H; and


20

Z is O, S, SO or SO₂; or

a pharmaceutically acceptable acid addition salt thereof.

23. A compound of claim 22 wherein Y⁴ is hydrogen, Q is CH=CH and R is methyl having 1S*,2S* relative stereochemistry:

25



30

-64-

24. The compound of claim 23 wherein X is 4-hydroxy, X^1 is hydrogen and Z is S.

25. The compound of claim 23 wherein X is 4-hydroxy, X^1 is hydrogen and Z is SO.

26. The compound of claim 23 wherein X is 4-hydroxy, X^1 is hydrogen and Z is SO₂.

27. A pharmaceutical composition comprising a neuroprotective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

28. A pharmaceutical composition comprising a neuroprotective amount of a compound of claim 12 and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising a neuroprotective amount of a compound of claim 22 and a pharmaceutically acceptable carrier.


30. A method of treating stroke or a CNS degenerative disease in man which comprises treatment with a neuroprotective amount of a compound of claim 1.

31. A method of treating stroke or a CNS degenerative disease in man which comprises treatment with a neuroprotective amount of a compound of claim 12.

32. A method of treating stroke or a CNS degenerative disease in man which comprises treatment with a neuroprotective amount of a compound of claim 22.

-65-

33. A compound of the formula



10

wherein

A and B are taken together and are oxygen, or A and B are taken separately and A is hydrogen and B is hydroxy;

15

R is hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

Q is S or CH=CH;

X² is hydrogen, (C₁-C₃)alkyl, halo, OR¹, OR², OCOR¹, COOR¹, SR¹, SR², NHR¹, NR¹R³, NHCOR¹, CONH₂ or

20

CN;

R¹ is hydrogen or (C₁-C₃)alkyl;


R² is a conventional hydroxy or mercaptan

protecting group;

R³ is a conventional amino protecting group;


25

Y⁵ and Y⁶ are taken together and are



30

-66-




; or

5

Y^5 and Y^6 are taken separately and
 Y^5 is hydrogen or OH, and Y^6 is


10



; or

15

Y^5 is hydrogen and Y^6 is



;

20

n is 0, 1, 2 or 3

m is 0, 1, 2, 3 or 4;

Q^1 is independently a value of Q as defined above;

25

X^3 is independently a value of X^2 as defined

above;

Z is O, S, SO or SO_2 ;

with the proviso that when A and B are taken
 separately, at least one of X^2 and X^3 is OR^2 , SR^2 or
 NR^1R^3 .

30

-67-


34. A compound of claim 33 wherein A and B are taken separately.

35. A compound of claim 34 wherein the conventional hydroxy or mercaptan protecting group is triisopropylsilyl, dimethyl-t-butylsilyl or benzyl.

36. A compound of claim 34 wherein the conventional amino protecting group is benzyloxycarbonyl.

37. A compound of claim 33 wherein A and B are taken together.

38. A compound of the formula




--- (V)


wherein

A and B are taken together and are oxygen, or A and B are taken separately and A is hydrogen and B is hydroxy;


E is



,



or



;

-68-

R is hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

Q is S or CH=CH;


X² is hydrogen, (C₁-C₃)alkyl, halo, OR¹, OR², COOR¹, OCOR¹, SR¹, SR², NHR¹, NR¹R³, NHCOR¹, CONH₂ or CN;

R¹ is hydrogen or (C₂-C₃)alkyl;


R² is a conventional hydroxy or mercaptan protecting group;

R³ is a conventional amino protecting group;

Y⁷ and Y⁸ are taken together and are




or



; or

Y⁷ and Y⁸ are taken separately, and Y⁷ is OH and Y⁸ is




;

-69-

Y^{10} is

5



10

Q^1 is independently a value of Q as defined above;
 X^3 is independently a value of X^2 as defined
 above;

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

15

with the proviso that when A and B are taken
 separately, at least one of X^2 and X^3 is OR^2 , SR^2 or
 NR^1R^3 .

39. A compound of claim 38 wherein A and B are
 taken separately.

20

40. A compound of claim 39 wherein the
 conventional hydroxy or mercaptan protecting group is
 triisopropylsilyl, dimethyl-*t*-butylsilyl or benzyl.

41. A compound of claim 39 wherein the
 conventional amino protecting group is benzyloxy-
 carbonyl.


25

42. A compound of claim 38 wherein A and B are
 taken together.

30

-70-

43. A compound of the formula



10

wherein

A and B are taken together and are oxygen, or A and B are taken separately and A is hydrogen and B is hydroxy;

15

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

Q and Q¹ are each independently S or CH=CH;

X² and X³ are each independently H, (C₁-C₃)alkyl, halo, OR¹, OR², COOR¹, OCOR¹, SR¹, SR², NHR¹, NR¹R³, NHCOR¹, CONH₂ or CN;

20

R¹ is H or (C₁-C₃)alkyl;

R² is a conventional OH or SH protecting group;

R³ is a conventional amino protecting group;

Y⁴ is H; and

25

Z is O, S, SO or SO₂;

with the proviso that when A and B are taken separately, at least one of X² and X³ is OR², SR² or NR¹R³.

30

44. A compound of claim 43 wherein A and B are taken separately.

45. A compound of claim 44 wherein the hydroxy or mercaptan protecting group is triisopropylsilyl, dimethyl-t-butylysilyl or benzyl.

-71-

46. A compound of claim 44 wherein the amino protecting group is benzyloxycarbonyl.

47. A compound of claim 43 wherein A and B are taken together.

5

10

15

20




25

30

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US90/00292

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): A61K 31/46; C07D 451/62; 451/06; 491/20 U.S. CL.: 514/278, 304; 546/18, 124, 125, 129, 131								
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border: 1px solid black; text-align: left;">Classification System</th> <th style="border: 1px solid black; text-align: left;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; vertical-align: top;">U.S.</td> <td style="border: 1px solid black; vertical-align: top;">514/278, 304 546/18, 124, 125, 129, 131</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	U.S.	514/278, 304 546/18, 124, 125, 129, 131		
Classification System	Classification Symbols							
U.S.	514/278, 304 546/18, 124, 125, 129, 131							
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black;">Category [*]</th> <th style="width: 60%; border: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; vertical-align: top; text-align: center;">A</td> <td style="border: 1px solid black; vertical-align: top;">US A, 4,393,069 (LANGBEIN) Published 12 July 1983 See entire document</td> <td style="border: 1px solid black; vertical-align: top;">1-7, 11, 27 and 30</td> </tr> </table>			Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	US A, 4,393,069 (LANGBEIN) Published 12 July 1983 See entire document	1-7, 11, 27 and 30
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³						
A	US A, 4,393,069 (LANGBEIN) Published 12 July 1983 See entire document	1-7, 11, 27 and 30						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the International filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>								
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; vertical-align: top;"> Date of the Actual Completion of the International Search 5 March 1990 </td> <td style="width: 50%; border: 1px solid black; vertical-align: top;"> Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">12 JUN 1990</div> </td> </tr> <tr> <td style="border: 1px solid black; vertical-align: top;"> International Searching Authority ISA/US </td> <td style="border: 1px solid black; vertical-align: top;"> Signature of Authorized Officer <div style="text-align: center;">  BERNARD DENTZ </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 5 March 1990	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">12 JUN 1990</div>	International Searching Authority ISA/US	Signature of Authorized Officer <div style="text-align: center;">  BERNARD DENTZ </div>		
Date of the Actual Completion of the International Search 5 March 1990	Date of Mailing of this International Search Report <div style="text-align: center; font-size: 1.2em; font-weight: bold;">12 JUN 1990</div>							
International Searching Authority ISA/US	Signature of Authorized Officer <div style="text-align: center;">  BERNARD DENTZ </div>							

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ¹² not required to be searched by this Authority, namely:
2. ☐ Claim numbers _____, because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out ¹³, specifically:
3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

- I. Claims 1-7, 11, 27 and 30 drawn to nortropanyl compounds in which Y¹ has a bond or a carbon chain attached to the Q¹ containing ring or where Y and Y² form an epoxide containing group.

(See Continuation Sheet 1)

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
1-7, 11, 27 and 30 and consists of the subject matter denoted as I. directly above.
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation Sheet 1

- II. Claims 1-4, 7-10, 27 and 30 drawn to nortroparyl compounds wherein Y has a hetero atom attached to the Q containing ring.
- III. Claims 12-21, 28 and 31 drawn to certain azamonocyclic compounds corresponding to group I.
- IV. Claims 22-26, 29 and 32 drawn to certain azamonocyclic compounds corresponding to group II.
- V. Claims 33-37 drawn to intermediates for the group I compounds.
- VI. Claims 33-37 drawn to intermediates for the group II compounds.
- VII. Claims 38-42 drawn to intermediates for the group III compounds.
- VIII. Claims 43-47 drawn to intermediates for the group IV compounds.

The hetero atom in the additional ring with respect to the term (Q) may represent thiophene rather than benzene represents one major structural difference. The azabicyclo ringsystems are independent and distinct from aza-monocyclic rings, e.g. piperidime.

The intermediate Groups V through VIII are not limited in use for making the alleged final products, Groups I through VI supra, being amines they are capable of forming crystalline salt with fluorosilicic acid wherein said fluorosilicates are moth proofing agents, or alternatively form condensation products when said amines interact with formaldelyde and thiocyanic acid wherein said condensation products are pickling inhibitors.